

Addendum to the report (23/12/2020) « Analysis of the WHO forms submitted by the MSIF panel members on Azathioprine and Rituximab as treatments of Multiple Sclerosis ».

On March 22, 2021, Mrs Laurson-Doube, Joanna Laurson-Doube PhD | International Consultant - Access to Treatment Multiple Sclerosis International Federation (MSIF), asked EAN Ethics and Quality Task Force to write an addendum to its previous report as two changes occurred in the MOLT COI declarations:

- One additional person to join MOLT, Prof Hans-Peter Hartung, to represent EAN
- One amended form by Prof Bassem Yamout.

After analysing the forms as transmitted by MSIF, the EAN Ethics and Quality Task Force members, using the same criteria detailed in its previous report concludes:

« Panellists Hans Peter Hartung and Bassem Yamout should have the right to speak on the topic of Rituximab but not to write the corresponding part of the panel report nor to vote on the final acceptance of the panel recommendation ».

A handwritten signature in black ink, appearing to read 'G. Deuschl'.

Günther DEUSCHL

A handwritten signature in black ink, appearing to read 'M. Stamelou'.

Maria STAMELOU

A handwritten signature in blue ink, appearing to read 'G. Moonen'.

Gustave MOONEN